Anti-Mouse CD93-158Gd

Catalog #: 3158015B  
Clone: AA4.1  
Package Size: 100 tests  
Storage: Store product at 4°C. Do not freeze.  
Cross Reactivity: Mouse  
Isotype: Rat IgG2b  
Formulation: Antibody stabilizer with 0.05% Sodium Azide

Technical Information

Validation: Each lot of conjugated antibody is quality control tested by CyTOF® analysis of stained cells using the appropriate positive and negative cell staining and/or activation controls.

Recommended Usage: The suggested use is 1 µl for up to 3 X 10^6 live cells in 100 µl. It is recommended that the antibody be titrated for optimal performance for each of the desired applications.

Mouse bone-marrow stained with 176Yb-anti-CD45R/B220 (RA36B2) and 158Gd-anti-CD93 (AA4.1). CD45+ CD11b- cells are displayed in the analysis.

Description

The AA4.1 monoclonal antibody reacts with mouse C1qRp, an approximately 130-140 kDa C-type lectin-like type I transmembrane protein.

References


Contact Information:

Sales: sales@DVSsciences.com | Support: support@DVSsciences.com  
www.DVSsciences.com | For assistance by phone: 855-DVS-CYTO

This product is intended for Research Use Only. This product is not intended for therapeutic or diagnostic purposes in humans or animals.  
This product contains antibodies manufactured by and sold under license from eBioscience and licensees thereof.

© 2011 DVS Sciences Inc. The trademarks mentioned herein are the property of DVS Sciences Inc. or their respective owners. DVS Sciences Inc. products are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to 6 months from date of sales for products used, handled and stored according to DVS Sciences, Inc. instructions. DVS Sciences, Inc. sole liability for the product is limited to replacement of the product or refund of the purchase price. Product may not be resold, modified for resale or used to manufacture commercial products without prior written approval from DVS Sciences Inc.